Living with Head and Neck Cancer and Coping with Dying when Treatments Fail

Otolaryngologic Clinics of North America

Volumn 42, Issue 1, 2009, Pages 171-184

  Elackattu, Alphi ^a   Jalisi, Scharukh ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Death; Dying; Palliative

Indexed keywords

ALPHA TOCOPHEROL; CANNABIS; CELECOXIB; CISPLATIN; DEXAMETHASONE; DRONABINOL; FATTY ACID; FLUOROURACIL; GLUCOCORTICOID; MEGESTROL ACETATE; MITOMYCIN; OPIATE; RETINOL;

ADD ON THERAPY; ADJUVANT THERAPY; AIRWAY OBSTRUCTION; BLEEDING; BRAIN DEATH; CACHEXIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAREGIVER; CAUSE OF DEATH; COPING BEHAVIOR; CYTOREDUCTIVE SURGERY; DEBRIDEMENT; DELIRIUM; DOCTOR PATIENT RELATION; DYING; DYSPHAGIA; EMERGENCY CARE; FAMILY; FAMILY COUNSELING; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HEALTH STATUS; HOSPICE CARE; HUMAN; HUMAN DIGNITY; HYGIENE; IMMUNOSUPPRESSIVE TREATMENT; MOUTH HYGIENE; MUCOSA INFLAMMATION; MUSCLE ATROPHY; MUSCLE WEAKNESS; NUTRITIONAL SUPPORT; OSTEOPOROSIS; PATIENT CARE; PREVALENCE; PROGNOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RESUSCITATION; REVIEW; SIDE EFFECT; TERMINAL CARE; WEIGHT GAIN; WOUND; WOUND CARE; XEROSTOMIA;

ADAPTATION, PSYCHOLOGICAL; ADVANCE DIRECTIVES; CACHEXIA; CAUSE OF DEATH; COMBINED MODALITY THERAPY; COMMUNICATION; HEAD AND NECK NEOPLASMS; HUMANS; PALLIATIVE CARE; PATIENT CARE TEAM; QUALITY OF LIFE; STOMATITIS; TREATMENT FAILURE; XEROSTOMIA;

EID: 58149105423     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2008.09.004     Document Type: Review

References (54)

1. Ellershaw, and Ward C. Care of the dying patient: the last hours or days of life. BMJ 326 (2003) 30-34
2. Cohen L.M., Poppel D.M., Cohn G.M., et al. A very good death: measuring quality of dying in end stage renal disease. J Palliat Med 4 (2001) 167-172
3. Fried T., van Droom C., O'Leary J., et al. Older persons' preference for site of terminal care. Ann Intern Med 131 (1999) 109-112
4. Steinhauser K.E., Clipp E.C., McNeilly C.M., et al. In search of a good death: observations of patients, families and providers. Ann Intern Med 132 (2000) 825-832
5. van den Beuken-van Everdingen M.H., de Rijke J.M., Kessels A.G., et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18 9 (2007) 1437-1449
6. Kowalski L.P., and Carvalho A.L. Natural history of untreated head and neck cancer. Eur J Cancer 36 (2000) 1032-1037
7. Hallenbeck J.L., Stratos G.A., and Katz S. Stanford faculty development program in end-of-life care (2000), Stanford, CA: Stanford University School of Medicine
8. Graf R., Hildebrandt B., Tilly W., et al. A non-randomized, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas. BMC Cancer 6 30 (2006) 1-9
9. Yogi V., and Singh O.P. Induction followed with concurrent chemoradiotherapy in advanced head and neck cancer. J Cancer Res Ther 1 4 (2005) 198-203
10. Mohanti B.K., Umapathy H., Bahadur S., et al. Short course palliative radiotherapy of 20 Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS study. Radiother Oncol 71 3 (2004) 275-280
11. Teymoortash A., Bien S., Dalchow C., et al. Selective high-dose intra-arterial cisplatin as palliative treatment for incurable head and neck cancer. Onkologie 27 6 (2004) 547-551
12. Forbes J.F. Palliative surgery in cancer patients: principles and potential of palliative surgery in patients with advanced cancer. Recent Results Cancer Res 108 (1988) 134-142
13. Lim R.Y. Laser tumor debulking. West Virginia Medical Journal 85 12 (1989) 530-532
14. Laccourreye O., Lawson G., Muscatello L., et al. Carbon dioxide laser debulking for obstructing endolaryngeal carcinoma: a 10-year experience. Ann Otol Rhinol Laryngol 108 5 (1999) 490-494
15. Phelan E., Lang E., Mahesh B.N., et al. Powered instrumentation in obstructing laryngeal tumours. J Laryngol Otol 121 3 (2007) 293-295
16. Paleri V., Stafford F.W., and Sammut M.S. Laser debulking in malignant upper airway obstruction. Head Neck 27 4 (2005) 296-301
17. Halfpenny W., and McGurk M. Stomal recurrence following temporary tracheostomy. J Laryngol Otol 115 (2001) 202-204
18. Grocott P. The palliative management of fungating malignant wounds. J Wound Care 9 1 (2000) 4-9
19. Morrison M. A colour guide to the nursing management of wounds (1992), Wolfe, London
20. Rumsey N., Clarke A., and White P. Exploring the psychosocial concerns of outpatients with disfiguring conditions. J Wound Care 12 7 (2003) 247-252
21. Katz M.R., Irish J.C., Devins G.M., et al. Communicating in the patient without a larynx. Head Neck 25 2 (2002) 103-112
22. Sandel H.D., and Davison S.P. Microsurgical reconstruction for radiation necrosis: an evolving disease. J Reconstr Microsurg 23 (2007) 225-230
23. Volpato L.E., Silva T.C., Oliveira T.M., et al. Radiation therapy and chemotherapy-induced oral mucositis. Rev Bras Otorrinolaringol 73 4 (2007) 562-568
24. Elting L.S., Cooksley C.D., Chambers M.S., et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68 (2007) 1110-1120
25. Aziz L., and Ebenfelt A. Mucosal secretion changes during radiotherapy in the oral cavity. Clin Oral Investig 11 3 (2007) 293-296
26. Patni N., Patni S., and Bapna A. The optimal use of granulocyte macrophage colony stimulating factor in radiation induced mucositis in head and neck squamous cell carcinoma. J Cancer Res Ther 1 3 (2005) 136-141
27. Veerasarn V., Phromratanapongse P., Suntornpong N., et al. Effect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Med Assoc Thai 89 12 (2006) 2056-2067
28. Penpattanagul S. Reduced incidence and severity of acute radiation mucositis by WF10 (IMMUNOKINE) as adjunct to standard of care in the management of head and neck cancer patients. J Med Assoc Thai 90 8 (2007) 1590-1600
29. Rydholm M., and Strang P. Physical and psychosocial impact of xerostomia in palliative cancer care: a qualitative interview study. Int J Palliat Nurs 8 7 (2002) 318-323
30. Jellema A.P., Slotman B.J., Doornaert P., et al. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69 3 (2007) 751-760
31. Davies A.N., Brailsford S.R., and Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 42 7 (2006) 698-702
32. Feio M., and Sapeta P. Xerostomia in palliative care. Acta Med Port 18 6 (2005) 459-465
33. Hargitai I.A., Sherman R.G., and Strother J.M. The effects of electrostimulation on parotid saliva flow: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 3 (2005) 316-320
34. Takakura K., Takaki S., Takeda I., et al. Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice. Bull Tokyo Dent Coll 48 2 (2007) 47-56
35. Kahn S.T., and Johnstone P.A. Management of xerostomia related to radiotherapy for head and neck cancer. Oncology (Williston Park) 19 14 (2005) 1827-1832 [discussion: 1832-4, 1837-9]
36. Wutzl A., Ploder O., Kermer C., et al. Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg 65 2 (2007) 255-260
37. Alho O.P., Hannula K., Luokkala A., et al. Differential prognostic impact of comorbidity in head and neck cancer. Head Neck 29 10 (2007) 913-918
38. Coatesworth A.P., Tsikoudas A., and MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol 116 (2002) 269-271
39. Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology center. Eur J Cancer Care 8 (1999) 133-136
40. Inagaki J., Rodriquez V., and Bodey G.P. Causes of death in cancer patients. Cancer 33 (1974) 568-571
41. Tisdale M.J. Cachexia in cancer patients. Nature 2 (2002) 862-871
42. Mantovani G., Mededdu C., Maccio A., et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidermiol Biomarkers Prev 13 (2004) 1651-1659
43. Dewys W.D. Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance. Clin Oncol 5 (1986) 251
44. Nguyen T.V., and Yueh B. Weight loss predicts morality after recurrent oral cavity and oropharyngeal carcinomas. Cancer 52 (2002) 72-91
45. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52 (2002) 72-91
46. Von Roenn J.H., and Paice J.A. Control of common, non-pain cancer symptoms. Semin Oncol 32 (2005) 200-210
47. Stitt T.N., Drujan D., Clarke B.A., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14 (2004) 395-403
48. Mantovani G., Maccio A., Bianchi A., et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25 (1995) 135-141
49. Nelson K., Walsh D., Deeter P., et al. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10 (1994) 14-18
50. Drug War Facts. States with legalized medical marijuana. Available at:. http://www.drugwarfacts.org/medicalm.htm Accessed May 20, 2008
51. Massi P., Valenti M., Vaccani A., et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104 4 (2008) 1091-1100
52. Parolaro D., and Massi P. Cannabinoids as potential new therapy for the treatment of gliomas. Expert Rev Neurother 8 1 (2008) 37-49
53. Ramer R., and Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100 1 (2008) 59-69
54. Naef M., Curatolo M., Petersen-Felix S., et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105 1-2 (2003) 79-88